Rachel Haurwitz, Caribou Biosciences CEO
‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy
Just like other cell therapy companies, Caribou Biosciences is entering the autoimmune disease field.
The Berkeley, CA-based biotech disclosed Thursday afternoon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
